Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs ...
CAMBRIDGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced a ...
CAMBRIDGE, England & STEVENAGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and ...
Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous ...
Cellular Origins announces the completion of a USD 40 million (EUR 34.3 million) over-subscribed Series A round. The Series A financing was led by Johnson & Johnson, through its corporate venture ...
Cellular Origins, a TTP company, acquired the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge while CEO of SOTIO Biotech US. The ACTIA Platform complements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results